To examine the therapeutic capacity of the CXCR4 mimic, we employed an established in vivo mouse model of early atherosclerosis, in which lesions develop in aortic root and arch over a 4–5-week time course of HFD44. Here, CXCR4 is linked to atherosclerosis.